Crossmark

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

Crossref DOI link: https://doi.org/10.1007/S13555-021-00558-0

Published: 2021-08

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Griffiths, Christopher http://orcid.org/0000-0001-5371-4427
de Bruin-Weller, Marjolein http://orcid.org/0000-0002-1249-6993
Deleuran, Mette http://orcid.org/0000-0003-0593-9925
Fargnoli, Maria Concetta http://orcid.org/0000-0002-7249-2556
Staumont-Sallé, Delphine http://orcid.org/0000-0002-4780-4212
Hong, Chih-ho http://orcid.org/0000-0001-9963-8319
Sánchez-Carazo, Jose http://orcid.org/0000-0002-1427-6003
Foley, Peter http://orcid.org/0000-0001-5891-5607
Seo, Seong Jun http://orcid.org/0000-0003-2915-839X
Msihid, Jérôme http://orcid.org/0000-0003-4733-5855
Chen, Zhen

Cyr, Sonya L. http://orcid.org/0000-0002-7231-0054
Rossi, Ana B. http://orcid.org/0000-0001-5345-678X
Funding

Funding for this research was provided by:

Sanofi

Regeneron Pharmaceuticals
License Information

Text and Data Mining valid from 2021-06-18

Version of Record valid from 2021-06-18
More Information

Article History

Received: 31 March 2021

Accepted: 24 May 2021

First Online: 18 June 2021

Change Date: 6 July 2021

Change Type: Update

Change Details: Error in the graphical abstract corrected and replaced with updated version

Document is current

Any future updates will be listed below